Zevra Therapeutics Conference Call Summary Company Overview - **Company**: Zevra Therapeutics (NasdaqGS: ZVRA) - **Focus**: Commercial-stage organization specializing in rare diseases, particularly Niemann-Pick disease type C (NPC) and vascular Ehlers-Danlos syndrome Key Points MIPLYFFA Performance - **Launch Success**: MIPLYFFA, the only disease-modifying therapy for NPC, launched successfully with a robust commercial performance [5][12] - **Revenue Growth**: Total revenue reached $106.5 million, marking a 30% quarter-over-quarter growth [12] - **Patient Enrollment**: 24 enrollment forms were submitted in Q4, indicating strong demand [12] Patient Demographics and Diagnosis - **Prevalence and Diagnosis**: Approximately 900 patients in the U.S. are estimated to have NPC, with 300-350 diagnosed [10][18] - **New Diagnoses**: Efforts in genetic testing and disease awareness are leading to an increase in newly diagnosed patients [13][18] - **Patient Journey**: The organization is focused on understanding the unique journey of each patient to improve diagnosis rates [20][23] Clinical Profile and Treatment Impact - **Disease Modification**: MIPLYFFA shows the ability to halt disease progression within 12 weeks, with long-term data supporting efficacy over 4-6 years [11][12] - **Safety Profile**: The therapy has an acceptable safety profile, which is crucial for patient acceptance [11] Geographic Expansion - **International Opportunities**: Zevra is exploring geographic expansion beyond the U.S. and Europe, with plans to increase access to MIPLYFFA [6][39] - **European Market**: The company is seeing a pull for the product in Europe, with 92 patients added in Q3, representing about 10% of the diagnosed population [39] Celiprolol Development - **Ongoing Trials**: Celiprolol is currently enrolling patients for vascular Ehlers-Danlos syndrome, with a focus on accelerating clinical development [6][52] - **Market Potential**: The U.S. prevalence for this condition is approximately 7,500 patients, indicating a significant market opportunity [58] Financial Strategy - **Capital Allocation**: The company emphasizes disciplined capital allocation, allowing for independent operation without reliance on capital markets [54][57] - **Investment Focus**: Investments are being made in MIPLYFFA, Celiprolol, and European market expansion [57] Awareness and Education Efforts - **Healthcare Provider Engagement**: Zevra is actively educating healthcare providers about NPC and MIPLYFFA to improve diagnosis and treatment rates [15][30] - **Genetic Testing Initiatives**: Collaborations with organizations like GeneDx are aimed at facilitating earlier diagnosis through genetic testing [15][16] Future Outlook - **Long-term Vision**: The company aims to continue focusing on MIPLYFFA's growth while developing Celiprolol and expanding its market presence [52][57] - **Market Strategy**: A flexible go-to-market strategy is being developed for Europe and other international markets, considering local dynamics and patient needs [40][43] Additional Insights - **Patient Retention**: High persistency rates are observed, with most patients remaining on therapy unless they progress to a point where therapy is no longer needed [26][29] - **Market Share**: Zevra has captured approximately 40%-50% market share in its first full year of MIPLYFFA's launch [24] This summary encapsulates the key insights from the conference call, highlighting Zevra Therapeutics' strategic focus, market performance, and future growth opportunities in the rare disease sector.

Core Insights - Zevra Therapeutics reported a Q4 net revenue of $34.1 million, marking a 31% growth quarter-over-quarter, and a full-year net revenue of $106.5 million for FY 2025, primarily driven by MIPLYFFA's net revenue of $87.4 million [1][6] - The company achieved a net income of $83.2 million for FY 2025, translating to earnings per share (EPS) of $1.40 basic and $1.35 diluted, a significant turnaround from a net loss of $(105.5) million in FY 2024 [12][33] - MIPLYFFA, the company's therapy for Niemann-Pick disease type C, has shown strong performance and is positioned for further growth, with market access reaching 68% of covered lives in the U.S. [2][7] Financial Highlights - Q4 2025 net revenue included $26.4 million from MIPLYFFA, $0.4 million from OLPRUVA, $5.6 million in net reimbursements from the Expanded Access Program (EAP), and $1.8 million in royalties [12][10] - Operating expenses for Q4 2025 were $23.0 million, with R&D expenses at $2.6 million, a decrease from $8.4 million in Q4 2024, while SG&A expenses rose to $20.4 million [12][10] - The company had cash, cash equivalents, and securities totaling $238.9 million as of December 31, 2025, indicating strong financial flexibility [12][10] Product and Pipeline Developments - MIPLYFFA has been designated as an Orphan Medicinal Product by the European Medicines Agency (EMA), with a Marketing Authorisation Application currently under review [7][13] - The company enrolled eight patients in the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome during Q4 2025, totaling 52 enrolled patients by year-end [4] - The EAP for MIPLYFFA has enrolled 113 patients globally, with a distribution agreement executed to broaden access beyond Europe [7][4] Strategic Focus - The company has relocated its global corporate headquarters to Boston to enhance access to specialized talent and is focused on executing multiple near-term growth opportunities in 2026 [2] - Zevra aims to create meaningful value for the rare disease community and its shareholders through disciplined execution of its strategic priorities [2][29]

Summary of Zevra Therapeutics FY Conference Call Company Overview - **Company**: Zevra Therapeutics (NasdaqGS: ZVRA) - **Industry**: Rare Disease Therapeutics - **Lead Product**: MIPLYFFA for Niemann-Pick disease type C (NPC) - **Financial Position**: Net revenue of $72.3 million in the first nine months of 2025, with a cash position of $230.4 million at the end of Q3 2025 [2][5][30] Core Points and Arguments Company Mission and Vision - Zevra aims to redefine possibilities in rare disease therapies, focusing on patient-centricity and accountability to stakeholders [4][5] - The company is in growth mode with a late-stage pipeline and geographic expansion plans [5][10] Product and Market Performance - MIPLYFFA received FDA approval in September 2024 and has orphan drug exclusivity until 2031 [5][6] - The product has achieved approximately 40% penetration of the diagnosed patient population within the first 12 months post-launch, a notable achievement in the rare disease space [10][19] - The company is expanding access to MIPLYFFA in Europe, with an MAA under review by the EMA [5][11] Pipeline and Future Growth - Zevra has a diversified portfolio including OLPRUVA for urea cycle disorders and AZSTARYS, with various products under development [6][28] - Celiprolol is in a pivotal phase 3 trial for vascular Ehlers-Danlos syndrome (VEDS) [28] - The company is leveraging AI for patient identification and diagnosis, enhancing its market reach [22][39] Financial Discipline and Strategy - Strong balance sheet with $230.4 million in cash and $61 million in debt [30] - The company monetized a pediatric priority review voucher for $150 million, adding non-dilutive capital [13] - Focus on sustainable growth through disciplined investments and prioritization of high-value opportunities [9][30] Important but Overlooked Content - The company is actively working on expanding its geographic reach beyond the U.S. and Europe, with distribution agreements in place for markets outside these regions [25][50] - The potential for patent term extension could significantly impact the company's valuation, with a ruling expected in 2026 [52][53] - The total addressable market (TAM) for NPC is estimated between 300 to 900 patients in the U.S., with ongoing efforts to identify undiagnosed patients [21][23] Conclusion Zevra Therapeutics is positioned for significant growth in the rare disease therapeutics market, driven by its innovative product MIPLYFFA, a strong financial foundation, and strategic expansion efforts. The company is focused on enhancing patient access and leveraging its pipeline to solidify its market presence.

Financial Performance & Cash Position - Zevra exited Q3 2025 with a strong cash position of $230.4 million[8], and total debt of $61.3 million[44] - The company generated net revenue of $72.3 million in the 9-month period[8], and $26.1 million for Q3 2025[43] - Q3 2025 net loss was $(0.5) million, or $(0.01) per basic and diluted share[43] Product Portfolio & Pipeline - MIPLYFFA adoption achieved in approximately 40% of diagnosed Niemann-Pick Disease Type C (NPC) patients within the first year of launch[13] - Payor coverage for MIPLYFFA reached 66% of covered lives as of Q3 2025[24] - Approximately 80% of patients who participated in the Phase 2/3 clinical trial for MIPLYFFA took miglustat[20] - Celiprolol Phase 3 DiSCOVER trial is ongoing for Vascular Ehlers-Danlos Syndrome (VEDS), with 44 of 150 patients enrolled as of Q3 2025[40] - For VEDS patients on celiprolol, the annual major vascular event rate is approximately 5% compared to approximately 12% in untreated patients[40] Market & Regulatory - Approximately 900 individuals in the U S live with NPC, of which 300-350 are diagnosed or treated[27] - Approximately 1,100 individuals are living with NPC in Europe[27] - MAA for Arimoclomol is under review by the EMA[8, 13]

Core Insights - Zevra Therapeutics reported a net revenue of $26.1 million for Q3 2025, significantly up from $3.7 million in Q3 2024, primarily driven by MIPLYFFA net revenue of $22.4 million [2][6][31] - The company is focused on expanding its presence in the rare disease market, particularly through the strong performance of MIPLYFFA for Niemann-Pick disease type C [3][28] Financial Highlights - Q3 2025 net revenue was $26.1 million, including $22.4 million from MIPLYFFA, $0.1 million from OLPRUVA, and $2.4 million in net reimbursements from the French EAP for arimoclomol [6][31] - Operating expenses for Q3 2025 were $20.4 million, down from $27.2 million in Q3 2024, with R&D expenses decreasing to $3.4 million from $10.9 million [11][31] - The net loss for Q3 2025 was $(0.5) million, or $(0.01) per share, compared to a net loss of $(33.2) million, or $(0.69) per share, in Q3 2024 [11][31] Product Performance - MIPLYFFA has achieved a market access rate of 66% of covered lives, with 137 prescription enrollment forms submitted since its launch [7] - OLPRUVA has reached an 81% market access rate, with 30 prescription enrollment forms submitted [7] - The company is evaluating options for OLPRUVA while maintaining product availability and support services for patients [7] Pipeline and Innovation - A Marketing Authorization Application for arimoclomol for Niemann-Pick disease type C has been validated and is under review by the European Medicines Agency [7] - Celiprolol, an investigational candidate for Vascular Ehlers-Danlos Syndrome, has restarted enrollment in the Phase 3 DiSCOVER trial [27] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and securities totaling $230.4 million, indicating sufficient financial resources to execute strategic priorities [11][31]

Core Insights - Zevra Therapeutics reported Q2 2025 net revenue of $25.9 million, significantly up from $4.4 million in Q2 2024, driven primarily by product net revenue of $21.8 million from MIPLYFFA [1][8] - The company completed the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) for $150 million, enhancing its balance sheet as it advances commercial launches and development programs [1][5] - Zevra submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for arimoclomol, aimed at treating Niemann-Pick Disease Type C [1][7] Commercial Highlights - MIPLYFFA achieved 7 prescription enrollments in Q2 2025, totaling 129 since its launch, with market access reaching 52% of covered lives [7] - OLPRUVA saw 1 prescription enrollment in Q2 2025, bringing the total to 29, with market access increasing to 79% of covered lives [7] Financial Highlights - Total revenue for Q2 2025 was $25.9 million, including $21.5 million from MIPLYFFA, $0.3 million from OLPRUVA, and $2.6 million in net reimbursements for arimoclomol [8] - Operating expenses were $24.2 million, with R&D expenses decreasing to $3.4 million, while SG&A expenses increased to $20.8 million [14] - The company reported a net income of $74.7 million for Q2 2025, compared to a net loss of $19.9 million in Q2 2024 [10][14] Pipeline and Innovation Highlights - Arimoclomol has been designated as an Orphan Medicinal Product by the EMA, and the company is on track with its guidance for submission in the second half of 2025 [7][17] - Zevra enrolled 7 patients in the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome during Q2 2025, totaling 39 enrolled patients [7] Corporate Highlights - As of June 30, 2025, Zevra's cash, cash equivalents, and securities totaled $217.7 million, providing sufficient resources for strategic priorities [14] - The company has granted inducement equity awards to 9 individuals totaling 54,875 shares of restricted stock units and 49,750 options to purchase common stock [15][16]

Company Overview - Zevra Therapeutics is focused on bringing life-changing therapeutics to the rare disease community[9] - The company has two commercial-stage rare disease products and an advanced clinical development pipeline[8,82] - Zevra has a strong financial position with $217 million in cash, cash equivalents, and investments as of April 1, 2025, including $687 million as of March 31, 2025, plus $1483 million net proceeds from a PRV sale[8,81] Product Portfolio - MIPLYFFA (arimoclomol) is FDA-approved for Niemann-Pick Disease Type C (NPC) and launched in November 2024[20] - Approximately 900 individuals in the U S live with NPC, with 300-350 diagnosed or treated[38] - OLPRUVA (sodium phenylbutyrate) for oral suspension is FDA-approved for Urea Cycle Disorders (UCD) in patients weighing 20 kg or greater and with a body surface area (BSA) of 12 m2 or greater[20,50] - Approximately 1,100 individuals are diagnosed with UCDs in the U S [59] Pipeline Development - The company is targeting an EMA MAA submission for arimoclomol in Europe in the second half of 2025[49] - Celiprolol is in Phase 3 development for Vascular Ehlers-Danlos Syndrome (VEDS), with IP through 2038[20] - Approximately 7,500 individuals in the U S are diagnosed with VEDS[74]

Financial Data and Key Metrics Changes - In Q4 2024, the company reported net revenue of $12 million, which included $10.1 million from MIPLYFFA, $0.1 million from OLPRUVA, and $1.1 million from net reimbursements from the French EAP for arimoclomol [41][44] - The full year 2024 net revenue was $23.6 million, with a net loss of $105.5 million or $2.28 per share, compared to a net loss of $46 million or $1.30 per share in 2023 [44][46] - Operating expenses for Q4 were $24.5 million, with R&D expenses decreasing to $8.4 million, while SG&A expenses increased to $16.1 million [43][45] Business Line Data and Key Metrics Changes - MIPLYFFA's launch exceeded expectations, with 109 patient enrollment forms received in Q4, reflecting strong demand in the NPC community [10][23] - OLPRUVA saw four new enrollments in Q4, an increase from three in Q3, with market access remaining consistent at 76% of covered lives [12][35] Market Data and Key Metrics Changes - The company estimates approximately 900 people with NPC in the U.S., with 300 to 350 diagnosed, indicating a significant market opportunity for MIPLYFFA [24][28] - The European market is expected to have around 1,100 patients living with NPC, with plans to submit a marketing authorization application in the second half of 2025 [11][53] Company Strategy and Development Direction - The company aims to expand MIPLYFFA's availability outside the U.S. and is focused on regulatory submissions in Europe [11][20] - The strategic plan includes four pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation [7][19] - The company is rationalizing its in-house discovery efforts and outsourcing activities to focus investments where there is the greatest potential for impact [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early success of MIPLYFFA and the potential for significant market penetration in both the U.S. and Europe [20][28] - The company is focused on building financial strength and disciplined capital allocation to support long-term transformation [19][47] Other Important Information - The company refinanced existing debt and completed a secondary offering, providing financial stability [19] - A priority review voucher was monetized for $150 million, expected to provide non-dilutive capital for future growth [20][46] Q&A Session Summary Question: Can you provide guidance on the European filing timeline? - Management indicated plans to file in the second half of 2025 and is confident in the acceptance of the filing based on improved long-term data [53][56] Question: How do you expect the European market dynamics to affect patient identification? - The European market is more mature, with more patients diagnosed and treated due to the long-standing presence of miglustat [53] Question: Can you provide more quantitative details on MIPLYFFA sales during the quarter? - MIPLYFFA revenue of $10.1 million included initial patient dispenses and refills, with inventory levels maintained at target levels [65] Question: What is the expected long-term net patient addition rate? - The focus will be on finding diagnosed but untreated patients, with expectations for steady growth in patient enrollments [67] Question: How many patients are currently treated at centers of excellence? - Most diagnosed patients have connections to centers of excellence, with ongoing efforts to expand treatment access [78] Question: What is the average time from enrollment to reimbursement? - It is too early to provide specifics, but initial experiences indicate a quick turnaround for some patients [104] Question: Have there been any patient denials for enrollment? - A few patients have faced initial denials, but the company has robust support systems in place to assist them [108]